Biotech News

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Earnings

~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~ ~ Record Number of Patients and

Related news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

Stock data

Close
13.45 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States